Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Pankiewicz, Joanna E ^a   Guridi, Maitea ^a   Kim, Jungsu ^b,c   Asuni, Ayodeji A ^a   Sanchez, Sandrine ^a   Sullivan, Patrick M ^d,e   Holtzman, David M ^b   Sadowski, Martin J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; Neurodegeneration; Therapy; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; FEMALE; HUMAN; MEMORY; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MEMORY; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID;

EID: 84927547425     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0075-0     Document Type: Article

References (49)

1. Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med 2010, 362(4):329-344. 10.1056/NEJMra0909142
2. Selkoe DJ: Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011, 17(9):1060-1065. 10.1038/nm.2460
3. Liu CC, Kanekiyo T, Xu H, Bu G: Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013, 9(2):106-118. 10.1038/nrneurol.2012.263
4. Mahley RW, Weisgraber KH, Huang Y: Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009, 50 Suppl: S183-S188.
5. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA: Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991, 252(5014):1817-1822. 10.1126/science.2063194
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Tanzi RE, Gusella JF, Small GW, Roses AD, Pericak-Vance MA, Haines JL: Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995, 45(7):1323-1328. 10.1212/WNL.45.7.1323
7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261(5123):921-923. 10.1126/science.8346443
8. Strittmatter W, Roses A: Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 1996, 19: 53-77. 10.1146/annurev.ne.19.030196.000413
9. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994, 7(2):180-184. 10.1038/ng0694-180
10. West HL, Rebeck GW, Hyman BT: Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 1994, 175(1-2):46-48. 10.1016/0304-3940(94)91074-X
11. Ma J, Brewer BH, Potter H, Brewer HB Jr: Alzheimer Ab neurotoxicity: promotion by antichymotrypsin, apoE4; inhibition by Ab-related peptides. Neurobiol Aging 1996, 17: 773-780. 10.1016/0197-4580(96)00112-1
12. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li YS, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T: A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol 2004, 165(3):937-948. 10.1016/S0002-9440(10)63355-X
13. Kuszczyk MA, Sanchez S, Pankiewicz J, Kim J, Duszczyk M, Guridi M, Asuni AA, Sullivan PM, Holtzman DM, Sadowski MJ: Blocking the interaction between apolipoprotein E and abeta reduces intraneuronal accumulation of abeta and inhibits synaptic degeneration. Am J Pathol 2013, 182(5):1750-1768. 10.1016/j.ajpath.2013.01.034
14. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP: Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006, 24(3):516-524. 10.1016/j.nbd.2006.08.017
15. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T: Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A 2006, 103(49):18787-18792. 10.1073/pnas.0604011103
16. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N: Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999, 103(11):1579-1586. 10.1172/JCI6172
17. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N: Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe 2. J Clin Invest 1998, 102(1):130-135. 10.1172/JCI2673
18. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N: Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997, 272(29):17972-17980. 10.1074/jbc.272.29.17972
19. Asuni AA, Guridi M, Pankiewicz JE, Sanchez S, Sadowski MJ: Modulation of amyloid precursor protein expression reduces beta-amyloid deposition in a mouse model. Ann Neurol 2014, 75(5):684-699. 10.1002/ana.24149
20. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain A beta burden in Alzheimer's disease model. Nat Neurosci 2002, 5(5):452-457.
21. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82: 239-259. 10.1007/BF00308809
22. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J: Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 1998, 57(7):674-683. 10.1097/00005072-199807000-00004
23. Wisniewski T, Lalowski M, Golabek AA, Vogel T, Frangione B: Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 1995, 345(8955):956-958. 10.1016/S0140-6736(95)90701-7
24. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM: Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009, 64(5):632-644. 10.1016/j.neuron.2009.11.013
25. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ: Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14(8):837-842. 10.1038/nm1782
26. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007, 27(11):2866-2875. 10.1523/JNEUROSCI.4970-06.2007
27. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P: Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8(8):1051-1058. 10.1038/nn1503
28. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM: Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 2011, 3(89):89ra57. 10.1126/scitranslmed.3002156
29. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM: Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000, 97: 2892-2897. 10.1073/pnas.050004797
30. Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, rbel-Ornath M, Betensky R, Davidson BL, Hyman BT: Gene transfer of human apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 2013, 5(212):212ra161. 10.1126/scitranslmed.3007000
31. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid b-peptide deposition. Nat Genet 1997, 17(3):263-264. 10.1038/ng1197-263
32. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM: Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein Transgenic mice. J Neurosci 2003, 23(21):7889-7896.
33. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT: Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 2012, 32(43):15181-15192. 10.1523/JNEUROSCI.1542-12.2012
34. Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL: Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 2012, 135(Pt 7):2155-2168. 10.1093/brain/aws127
35. Marques MA, Owens PA, Crutcher KA: Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain. J Mol Neurosci 2004, 24(1):73-80. 10.1385/JMN:24:1:073
36. Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM: Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med 2012, 209(12):2149-2156. 10.1084/jem.20121274
37. Deane R, Wu ZH, Sagare A, Davis J, Yan SD, Hamm K, Xu F, Parisi M, Larue B, Hu HW, Spijkers P, Guo H, Song XM, Lenting PJ, van Nostrand WE, Zlokovic BV: LRP/amyloid beta-peptide interaction mediates differential brain efflux of A beta isoforms. Neuron 2004, 43(3):333-344. 10.1016/j.neuron.2004.07.017
38. Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G: Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci 2013, 33(49):19276-19283. 10.1523/JNEUROSCI.3487-13.2013
39. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM: Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem 2012, 287(17):13959-13971. 10.1074/jbc.M111.288746
40. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM: ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci U S A 2013, 110(19):E1807-E1816. 10.1073/pnas.1220484110
41. Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, LaDu MJ: Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener 2014, 9: 2. 10.1186/1750-1326-9-2
42. Tayeb HO, Murray ED, Price BH, Tarazi FI: Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 2013, 13(7):1075-1084. 10.1517/14712598.2013.789856
43. Kaufer D, Gandy S: APOE ε4 and bapineuzumab: infusing pharmacogenomics into Alzheimer disease therapeutics. Neurology 2009, 73(24):2052-2053. 10.1212/WNL.0b013e3181c6784a
44. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, Van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73(24):2061-2070. 10.1212/WNL.0b013e3181c67808
45. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011, 7(4):367-385. 10.1016/j.jalz.2011.05.2351
46. Lambracht-Washington D, Rosenberg RN: Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013, 15(84):319-326.
47. Lemere CA: Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 2013, 8(1):36. 10.1186/1750-1326-8-36
48. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001, 98(15):8850-8855. 10.1073/pnas.151261398
49. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L: Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012, 69(2):198-207. 10.1001/archneurol.2011.1538